Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: SGLT2 inhibitor


Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor

June 8th 2017

Shortly after initiation, SGLT2 inhibitors were associated with approximately twice the risk of diabetic ketoacidosis as were DPP4 inhibitors, although cases of diabetic ketoacidosis leading to hospitalization were infrequent (NEJM)

Categories: Medication, News
Tags: Ketoacidosis, SGLT2 inhibitor

Categories: Medication
Tags: Ketoacidosis, SGLT2 inhibitor

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

April 5th 2017

Despite improvements in glucose control and reduction in body weight, therapy with dapagliflozin exerted no significant effect on HDL cholesterol levels and HDL functionality (Cardiovascular Diabetology)

Categories: Medication, News
Tags: dapagliflozin, HDL cholesterol, SGLT2 inhibitor, Type 2 Diabetes

Categories: Medication
Tags: dapagliflozin, HDL cholesterol, SGLT2 inhibitor, Type 2 Diabetes

Sodium Glucose Cotransporter 2 Inhibition in the Diabetic Kidney

February 16th 2016

The findings expand and refine our understanding of SGLT2 and its inhibition, have relevance for clinical practice, and will help interpret ongoing clinical trials on the long-term safety and cardiovascular effects of SGLT2 inhibitors (Medscape) – Registration required

Categories: Nephrology, News
Tags: SGLT2 inhibitor

Categories: Nephrology
Tags: SGLT2 inhibitor

The renal threshold for glucose re-absorption predicts diabetes improvement by sodium glucose co-transporter 2 inhibitor therapy

January 8th 2016

These findings indicate that patients who have higher renal threshold for glucose re-absorption can be expected to more effectively respond to SGLT2 inhibitor therapy in terms of lowering HbA1c level (Journal of Diabetes Investigation)

Categories: Nephrology, News
Tags: HbA1c, SGLT2 inhibitor

Categories: Nephrology
Tags: HbA1c, SGLT2 inhibitor

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaNovo NordiskNapp Diabetes

Silver Sponsors

AmgenAbbott Diabetes CareSanofi DiabetesWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM closed-loop dapagliflozin DPP4 Dulaglutide elderly Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NICE OGTT pioglitazone pregnancy retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2019 · Enterprise Pro Theme on Genesis Framework · WordPress · Log in